NDSIB
BMRN icon

North Dakota State Investment Board’s BioMarin Pharmaceuticals BMRN Stock Holding History

North Dakota State Investment Board’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$314K Sell
5,558
-1,180
-18% -$68.8K 0.01% 614
2025
Q4 		$400K Buy
+6,738
New +$367K 0.01% 593

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

North Dakota State Investment Board's BMRN Position: Q1 2026 in Review

North Dakota State Investment Board reduced its BioMarin Pharmaceuticals (BMRN) stake by 18% in Q1 2026, selling an estimated $68.8K and leaving 5,558 shares worth $314K. The position accounts for 0.01% of the portfolio, ranked #614.

North Dakota State Investment Board first reported a position in BMRN in Q4 2025 and has held it in 2 quarters since. The position peaked at $400K in Q4 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • North Dakota State Investment Board held 5,558 shares of BioMarin Pharmaceuticals worth $314K as of Q1 2026.
  • North Dakota State Investment Board sold 1,180 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $68.8K.
  • BioMarin Pharmaceuticals made up 0.01% of North Dakota State Investment Board's portfolio in Q1 2026, its #614 holding.
  • North Dakota State Investment Board first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • North Dakota State Investment Board's BioMarin Pharmaceuticals position peaked at $400K in Q4 2025.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on North Dakota State Investment Board's 13F filing for Q1 2026, filed 8 May 2026.